Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ofranergene obadenovec - VBL Therapeutics

Drug Profile

Ofranergene obadenovec - VBL Therapeutics

Alternative Names: GT-111; VB 111

Latest Information Update: 22 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vascular Biogenics
  • Developer Gynecologic Oncology Group; Massachusetts General Hospital; VBL Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Angiogenesis modulating agents; Gene expression modulators; Gene transference; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma; Ovarian cancer
  • Phase II Thyroid cancer
  • Preclinical Lung cancer; Malignant melanoma

Most Recent Events

  • 22 Feb 2019 9260915 - updated financing info in KDM
  • 20 Nov 2018 VBL Therapeutics has patent protection for VB-111 composition-of-matter in Japan and China
  • 16 Nov 2018 Efficacy and adverse events data from a the phase III GLOBE trial in Glioblastoma released by VBL Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top